A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial

[1]  A. Reyniès,et al.  A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  B. Garcia,et al.  Epigenetic and transcriptional control of the epidermal growth factor receptor (EGFR) regulates the tumor immune microenvironment in pancreatic cancer. , 2020, Cancer discovery.

[3]  C. Denkert,et al.  TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial , 2020, Clinical Cancer Research.

[4]  L. Bullinger,et al.  Single-cell analysis based dissection of clonality in myelofibrosis , 2019, Nature Communications.

[5]  J. Berlin,et al.  Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[7]  R. Rabadán,et al.  Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. , 2019, Cancer cell.

[8]  L. Bullinger,et al.  Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. , 2019, Blood.

[9]  P. Campbell,et al.  Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions , 2019, Nature Medicine.

[10]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[11]  Weiqun Peng,et al.  Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors. , 2018, Cancer cell.

[12]  B. Dörken,et al.  Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis , 2018, Leukemia.

[13]  R. Eils,et al.  Deciphering programs of transcriptional regulation by combined deconvolution of multiple omics layers , 2017, bioRxiv.

[14]  B. Dörken,et al.  CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. Dörken,et al.  EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia , 2017, Leukemia.

[16]  S. Miyano,et al.  Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. , 2017, Blood.

[17]  Aaron S. Meyer,et al.  JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2-Targeted Therapies. , 2016, Cancer research.

[18]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[19]  P. Zarogoulidis,et al.  Pancreatic cancer from bench to bedside: molecular pathways and treatment options. , 2016, Annals of translational medicine.

[20]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[21]  R. Scharpf,et al.  Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients , 2015, Nature Communications.

[22]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[23]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[24]  U. Mansmann,et al.  EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 , 2012, British Journal of Cancer.

[25]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[26]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[27]  David Olmos,et al.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Kleeff,et al.  Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. , 2011, Neoplasia.

[29]  Joon-Oh Park,et al.  Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy , 2011, Molecular Cancer Therapeutics.

[30]  R. Hruban,et al.  Pancreatic cancer , 2011, The Lancet.

[31]  P. Spellman,et al.  Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy , 2011, Nature Medicine.

[32]  Jimmy Lin,et al.  Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 , 2009, Nature Genetics.

[33]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  V. Kovač,et al.  Erlotinib in previously treated non-small-cell lung cancer , 2006 .

[35]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[36]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[37]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[38]  J. Tran van Nhieu,et al.  GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. , 2012, Journal of hepatology.

[39]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[40]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.